跳到正文
原文
Medical Xpress·· 2026-10-22精选AI 评分71

BlinPredict新工具助力儿童B-ALL免疫治疗精准分层

Personalized medicine breakthrough for childhood leukemia

AI 导读

2026年10月发表在《Blood Advances》的研究首次全面分析Blinatumomab治疗儿童B-ALL的复发风险因素。研究发现传统化疗风险指标(年龄/血常规/高危基因特征/治疗前的残留病灶)在免疫治疗中不再适用,需用BlinPredict工具结合首次治疗应答和遗传亚型(IKZF1plus/DUX4-rearranged)进行分层。

推荐理由

原文提出基于早期治疗应答和遗传特征的BlinPredict工具,挑战传统化疗风险预测模型,为免疫治疗时代儿童B-ALL的个体化治疗提供新依据。

正文 · 原文
iv tubing
Credit: Pixabay/CC0 Public Domain

Researchers from Newcastle University and Great Ormond Street Hospital have identified new predictors of relapse in children and young people with acute lymphoblastic leukemia (ALL) treated with the immunotherapy drug blinatumomab, as part of a U.K.-wide study.

Their findings challenge long-standing assumptions based on traditional chemotherapy treatments and could help doctors tailor treatment more precisely to individual patients.

Shaping UK treatment guidelines

Published in Blood Advances, the study is the first comprehensive analysis of relapse risk factors in children receiving blinatumomab as a replacement for parts of standard chemotherapy.

The findings suggest a more targeted approach could spare some children unnecessary chemotherapy while maintaining excellent outcomes and have already led to revisions of national U.K. treatment guidelines.

Anthony Moorman, joint lead author from Newcastle University, said, "Blinatumomab is transforming the treatment of childhood acute lymphoblastic leukemia, but until now we did not know whether the risk factors used for decades in chemotherapy-based treatment still applied.

"Our findings show that many of them do not. Instead, a child's early response to blinatumomab, together with specific genetic features of their leukemia, provides a much more accurate picture of relapse risk.

"This research will help clinicians identify which patients are likely to do exceptionally well with reduced chemotherapy and which will require a different treatment approach.

"Reducing exposure to chemotherapy has the potential to lessen side effects and improve quality of life, while ensuring that higher-risk patients receive the treatment they need."

Dr. Sujith Samarasinghe, consultant pediatric hematologist at GOSH and joint lead author, said, "Being able to accurately predict how this kinder, more effective medicine will help our patients means less chemotherapy, more days at school, more time at home and ultimately more time spent being children.

"We are already seeing the real-world impact of this work, with the findings now helping guide how children across the U.K. are treated."

The national study involved more than 200 young patients with B-cell acute lymphoblastic leukemia treated across 24 centers in the U.K. and Ireland.

Treatment response data were collected through regional laboratories and genetic testing, including whole-genome sequencing, was performed through NHS Genomics Laboratory Hubs before being analyzed centrally.

The study found many of the risk factors traditionally used to predict relapse in childhood acute lymphoblastic leukemia, including age, white blood cell count, high-risk genetic features and measurable residual disease before blinatumomab treatment, were no longer reliable indicators for patients receiving this immunotherapy-based approach.

Instead, the strongest predictor of future relapse was the amount of leukemia remaining after the first cycle of blinatumomab.

The team also identified two genetic subtypes, known as IKZF1plus and DUX4-rearranged leukemia, which were associated with a poorer response to treatment and a higher risk of relapse.

The power of early response

Using these findings, the researchers developed a new risk-stratification tool called BlinPredict, which combines early treatment response with genetic information to identify patients most at risk of their cancer returning.

Researchers say the findings mark an important step toward a new generation of treatment strategies designed specifically for the immunotherapy era.

Future work will focus on understanding why some leukemias are resistant to blinatumomab and on identifying risk factors in other patient groups, including adults with ALL.

Publication details

Miguel Vieira Martins et al., Early response and genetics define relapse risk after frontline blinatumomab in childhood B-ALL: A cohort study, Blood Advances (2026). DOI: 10.1182/bloodadvances.2026021026

Journal information: Blood Advances

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Personalized medicine breakthrough for childhood leukemia (2026, October 21) retrieved 21 October 2026 from https://medicalxpress.com/news/2026-10-personalized-medicine-breakthrough-childhood-leukemia.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com